Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for ion channels.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the channel in its native membrane environment in open, closed and inactivated forms and the ensemble virtual screening accounting for conformational mobility in each of these states. Tentative binding pockets are considered inside the pore, in the gating region and in the allosteric locations to cover the whole spectrum of possible mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P35498
UPID:
SCN1A_HUMAN
Alternative names:
Sodium channel protein brain I subunit alpha; Sodium channel protein type I subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.1
Alternative UPACC:
P35498; E9PG49; Q16172; Q585T7; Q8IUJ6; Q96LA3; Q9C008
Background:
The Sodium channel protein type 1 subunit alpha, also known as Nav1.1, plays a crucial role in the voltage-dependent sodium ion permeability of excitable membranes. This protein is pivotal in brain function, regulating neurotransmitter release in neurons and involved in sensory perception of mechanical pain, indicating its significant role in pain hypersensitivity.
Therapeutic significance:
Nav1.1 is linked to several neurological disorders, including Generalized epilepsy with febrile seizures plus 2, Dravet syndrome, and Developmental and epileptic encephalopathy 6B. Its involvement in these diseases highlights its potential as a target for therapeutic strategies aimed at modulating neuronal excitability and treating epilepsy.